Cytochrome P450-based cancer gene therapy: current status.
about
Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomasOxazaphosphorines: new therapeutic strategies for an old class of drugs.Prodrugs for improving tumor targetability and efficiency.Metabolism and transport of oxazaphosphorines and the clinical implications.A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.Gene therapy of liver cancer.
P2860
Cytochrome P450-based cancer gene therapy: current status.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cytochrome P450-based cancer gene therapy: current status.
@ast
Cytochrome P450-based cancer gene therapy: current status.
@en
type
label
Cytochrome P450-based cancer gene therapy: current status.
@ast
Cytochrome P450-based cancer gene therapy: current status.
@en
prefLabel
Cytochrome P450-based cancer gene therapy: current status.
@ast
Cytochrome P450-based cancer gene therapy: current status.
@en
P2093
P2860
P356
P1476
Cytochrome P450-based cancer gene therapy: current status.
@en
P2093
Stuart Naylor
Susan Kingsman
P2860
P304
P356
10.1517/14712598.2.8.857
P407
P577
2002-12-01T00:00:00Z